 Antibiotics have been a vital part of modern medicine for over 70 years but overuse and inappropriate use in humans and animals has led to dangerous bacteria developing deadly resistance. Drug resistant infections, often called superbogs, which can't be treated with the medicines we have today, are one of the world's most urgent health problems. Worldwide these drug resistant infections kill over 700,000 people every year and without action this number will continue to rise rapidly. Previously treatable infections and routine surgeries such as hip replacement and cesareans will be potentially fatal. Research to tackle drug resistant infections has been too long neglected. The last new class of antibiotics was developed in the 1980s. Of even greater concern we have not seen a new class of antibiotics to treat the dangerous gram-negative bacteria since 1962. The Wellcome Trust is committed to supporting scientists to work together with industry, governments and civil society to tackle this rapidly rising problem. New treatments are a priority. We need new antibiotics and innovative treatments. We need new diagnostics and we need new vaccines to prevent the spread of deadly infections. Through the CARB-X biopharmaceutical accelerator, promising research in all of these areas is now being supported. Public-private partnerships like CARB-X are vital to reinvigorate research and discovery. Wellcome has announced up to $155 million over five years to the CARB-X partnership. Drug discovery must work hand-in-hand with actions to ensure that antibiotics are available to all patients who need them in all countries and are used appropriately. Enabling responsible use in equitable access are conditions of CARB-X funding. We need to ensure that antibiotics existing and new are treated as a valuable resource and are used only for protecting and improving health. Global recognition of this urgent health threat has grown. However, we need to see more investment, more action and greater urgency. Wellcome is working with governments, industry and global health leaders to ensure concerted and coordinated action. Our goal is a world where excellent prevention and diagnosis delays drug resistance developing and where there is a pipeline of new treatments that are used appropriately and available to all patients who need them.